Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,274,752 papers from all fields of science
Search
Sign In
Create Free Account
Non-nucleoside Reverse Transcriptase Inhibitor
Known as:
NNRTI
A substance structurally unlike a nucleoside molecule that is capable of inhibiting the function of a reverse transcriptase. These compounds do not…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update
D. Bennett
,
R. Camacho
,
+15 authors
R. Shafer
PLoS ONE
2009
Corpus ID: 1709489
Programs that monitor local, national, and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines and…
Expand
Highly Cited
2007
Highly Cited
2007
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
B. Grinsztejn
,
B. Nguyen
,
+7 authors
R. Isaacs
The Lancet
2007
Corpus ID: 22735639
Highly Cited
2006
Highly Cited
2006
Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness
D. Bangsberg
,
Edward P Acosta
,
+5 authors
S. Deeks
AIDS (London)
2006
Corpus ID: 24743499
Objective:To compare the prevalence of resistance by adherence level in patients treated with non-nucleoside reverse…
Expand
Highly Cited
2006
Highly Cited
2006
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
P. Braitstein
,
M. Brinkhof
,
+12 authors
M. Egger
The Lancet
2006
Corpus ID: 14319754
Review
2005
Review
2005
British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008
B. Gazzard
HIV Medicine
2005
Corpus ID: 9431775
The 2008 BHIVA Guidelines have been updated to incorporate all the new relevant information (including presentations at the 15th…
Expand
Highly Cited
2005
Highly Cited
2005
Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis
S. Palmer
,
Mary F. Kearney
,
+11 authors
J. Coffin
Journal of Clinical Microbiology
2005
Corpus ID: 27473079
ABSTRACT To investigate the extent to which drug resistance mutations are missed by standard genotyping methods, we analyzed the…
Expand
Highly Cited
2004
Highly Cited
2004
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and…
K. Das
,
A. Clark
,
+20 authors
E. Arnold
Journal of Medicinal Chemistry
2004
Corpus ID: 11088302
Anti-AIDS drug candidate and non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125-R165335 (etravirine) caused an initial…
Expand
Highly Cited
2004
Highly Cited
2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
F. V. Leth
,
P. Phanuphak
,
+26 authors
J. Lange
The Lancet
2004
Corpus ID: 31412017
Highly Cited
2003
Highly Cited
2003
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
N. Friis‐Møller
,
R. Weber
,
+12 authors
J. Lundgren
AIDS (London)
2003
Corpus ID: 22814665
Objective: To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to…
Expand
Review
2002
Review
2002
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
P. Yeni
,
S. Hammer
,
+15 authors
P. Volberding
Journal of the American Medical Association (JAMA…
2002
Corpus ID: 2545081
OBJECTIVE New information warrants updated recommendations for the 4 central issues in antiretroviral therapy: when to start…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE